| Primary |
| Hypertension |
33.3% |
| Arteriosclerosis |
16.7% |
| Atrial Fibrillation |
16.7% |
| Macular Degeneration |
16.7% |
| Peripheral Vascular Disorder |
16.7% |
|
| Cerebral Haemorrhage |
50.0% |
| Renal Failure Chronic |
50.0% |
|
| Secondary |
| Atrial Fibrillation |
19.6% |
| Atrial Flutter |
14.5% |
| Product Used For Unknown Indication |
11.2% |
| Prophylaxis |
7.8% |
| Drug Use For Unknown Indication |
6.1% |
| Acute Myocardial Infarction |
4.5% |
| Essential Hypertension |
4.5% |
| Myocardial Ischaemia |
4.5% |
| Hypertension |
2.8% |
| Mitral Valve Incompetence |
2.8% |
| Rheumatoid Arthritis |
2.8% |
| Antiphospholipid Syndrome |
2.2% |
| Crohn's Disease |
2.2% |
| Deep Vein Thrombosis |
2.2% |
| Hypertensive Heart Disease |
2.2% |
| Ill-defined Disorder |
2.2% |
| Phlebitis |
2.2% |
| Renal Failure |
2.2% |
| Depression |
1.7% |
| Osteopenia |
1.7% |
|
| Drug Interaction |
9.3% |
| International Normalised Ratio Increased |
9.3% |
| Muscle Haemorrhage |
9.3% |
| Glomerulonephritis |
7.0% |
| Haematoma |
7.0% |
| Rash Maculo-papular |
7.0% |
| Syncope |
7.0% |
| Haemorrhagic Anaemia |
4.7% |
| Melaena |
4.7% |
| Pancreatitis Acute |
4.7% |
| Skin Haemorrhage |
4.7% |
| Subdural Haemorrhage |
4.7% |
| Toxicity To Various Agents |
4.7% |
| Bone Pain |
2.3% |
| Cerebral Haemorrhage |
2.3% |
| Cholangitis |
2.3% |
| Depressed Level Of Consciousness |
2.3% |
| Dyskinesia |
2.3% |
| Henoch-schonlein Purpura |
2.3% |
| Liver Disorder |
2.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
36.7% |
| Atrial Fibrillation |
9.8% |
| Drug Use For Unknown Indication |
5.6% |
| Pulmonary Arterial Hypertension |
5.6% |
| Hypertension |
4.3% |
| Rheumatoid Arthritis |
4.1% |
| Atrial Flutter |
3.3% |
| Multiple Myeloma |
3.3% |
| Thrombosis Prophylaxis |
3.3% |
| Depression |
2.8% |
| Hypertensive Heart Disease |
2.8% |
| Chronic Myeloid Leukaemia |
2.4% |
| Pain |
2.4% |
| Pulmonary Embolism |
2.4% |
| Chronic Lymphocytic Leukaemia |
2.2% |
| Cardiac Disorder |
2.0% |
| Ill-defined Disorder |
2.0% |
| Hiv Infection |
1.7% |
| Peripheral Arterial Occlusive Disease |
1.7% |
| Prophylaxis |
1.7% |
|
| Renal Failure |
8.8% |
| Tremor |
8.8% |
| Pulmonary Embolism |
7.0% |
| Breast Cancer |
5.3% |
| Hypotension |
5.3% |
| Rash |
5.3% |
| Renal Failure Acute |
5.3% |
| Renal Failure Chronic |
5.3% |
| Sudden Death |
5.3% |
| Tubulointerstitial Nephritis |
5.3% |
| Ventricular Fibrillation |
5.3% |
| Weight Decreased |
5.3% |
| Alanine Aminotransferase Increased |
3.5% |
| Biopsy Liver Abnormal |
3.5% |
| Bradycardia |
3.5% |
| Cardiac Failure |
3.5% |
| Cerebral Ischaemia |
3.5% |
| Chronic Obstructive Pulmonary Disease |
3.5% |
| Death |
3.5% |
| Dyspnoea |
3.5% |
|
| Interacting |
| Atrial Fibrillation |
28.3% |
| Atrial Flutter |
14.1% |
| Essential Hypertension |
7.6% |
| Product Used For Unknown Indication |
7.6% |
| Helicobacter Gastritis |
6.5% |
| Myocardial Ischaemia |
4.3% |
| Osteoporosis |
4.3% |
| Heart Valve Replacement |
3.3% |
| Hypertension |
3.3% |
| Hypertonic Bladder |
3.3% |
| Arteriosclerosis Coronary Artery |
2.2% |
| Attention Deficit/hyperactivity Disorder |
2.2% |
| Benign Prostatic Hyperplasia |
2.2% |
| Cardiac Failure |
2.2% |
| Chronic Myeloid Leukaemia |
2.2% |
| Pulmonary Embolism |
2.2% |
| Acute Endocarditis |
1.1% |
| Anticoagulant Therapy |
1.1% |
| Cardiac Disorder |
1.1% |
| Dyspepsia |
1.1% |
|
| Drug Interaction |
16.7% |
| International Normalised Ratio Increased |
13.9% |
| Prothrombin Time Prolonged |
8.3% |
| Renal Failure Chronic |
8.3% |
| Haematochezia |
5.6% |
| Labelled Drug-drug Interaction Medication Error |
5.6% |
| Obstructive Airways Disorder |
5.6% |
| Renal Failure |
5.6% |
| Supraventricular Tachycardia |
5.6% |
| Chest Discomfort |
2.8% |
| Coagulopathy |
2.8% |
| Haemorrhage Urinary Tract |
2.8% |
| Haemorrhagic Anaemia |
2.8% |
| Neutrophil Count Decreased |
2.8% |
| Retroperitoneal Haemorrhage |
2.8% |
| Subarachnoid Haemorrhage |
2.8% |
| Vertigo |
2.8% |
| Weight Decreased |
2.8% |
|
